Company intelligence / Profile preview

Lifesome Therapeutics

Madrid, Community of Madrid, Spainlifesometherapeutics.com ↗

Ownership: Private
Employees: ~8
Development stage: Preclinical

Overview

Lifesome Therapeutics is developing Ohmline, a novel lipid-based nanocarrier that not only delivers drugs but also exhibits intrinsic antitumoral and antimicrobial activities. Preclinical studies have shown efficacy in vitro and in vivo models of cancer and bacterial infections with minimal toxicity. The company is currently focused on expanding the platform to gene therapy and theragnostic applications.[1][2][3]

Therapeutic areas: OncologyImmunologyOtherDermatologyNeurologyInfectious Diseases
Modalities: Lipid-based nanocarriersNanoparticlesHydrogels3D printable nanomaterials for drug deliveryEncapsulated small molecules and biologics[1][3]
Industry: Biotech

Drug pipeline

1 asset

ohmline

Pre-clinical

Indications: Cancer, Antimicrobial infections

Beyond the preview

Go deeper on Lifesome Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lifesome Therapeutics.

Explore the full profile